Trial Search Results

Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2

To better understand the mechanisms leading to lymphedema development in breast cancer survivors, and the implications for potential innovative approaches to the screening, prevention and treatment of this condition.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: California Breast Cancer Research Program

Stanford Investigator(s):


Inclusion Criteria:

   - Patients enrolled in the proposed studies must be survivors of breast cancer at a time
   point at least 4 years following the initial surgery and radiotherapy for the disease.

   - Patients must have a history of unilateral axillary lymph node dissection.

   - Patients referred to, or that receive their care within the Stanford University Breast
   Cancer Program and the Stanford Center for Lymphatic and Venous Disorders.

   - Patients will be required to have the capacity to provide informed consent.

Exclusion Criteria:

   - Patients with other serious systemic illness (renal failure, hepatic dysfunction,
   congestive heart failure, neurological or psychological impairment) that would
   confound the study or impair the patients' ability to participate.

   - Patients will not be enrolled if they are taking drugs that affect carbohydrate

   - Patients with recurrent breast cancer or other forms of pre-existing lymphedema will
   be ineligible.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Anne Marie Vaillant-Newman